Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 844

August will see the second annual Longevity Summit take place in Dublin. Packed with keynote presentations by leading experts in the aging field, the summit will showcase some of the latest – and most exciting – research and innovations in the longevity space.

Longevity. Technology: One of the Longevity Summit’s most-anticipated speakers is eminent gerontologist Dr Aubrey de Grey. Since the launch of the Longevity Escape Velocity Foundation, which Dr de Grey announced at Dublin last year, news on progress of its flagship research programme Robust Mouse Rejuvenation has been keenly awaited, as has further details on its research into transplants on demand.

Earlier this week, we caught up with Dr de Grey to find out more about the conference, its speakers and agenda, and today we dig into what he and LEV Foundation have been up to.

Read more | >

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way.

On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older.

It could be available for seniors as soon as this fall, pending a recommendation for its use from the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, which next meets in June.

Read more | >

A deep slumber might help buffer against memory loss for older adults facing a heightened burden of Alzheimer’s disease, new research from the University of California, Berkeley, suggests.

Deep sleep, also known as non-REM , can act as a “cognitive reserve factor” that may increase resilience against a protein in the brain called that is linked to caused by dementia. Disrupted sleep has previously been associated with faster accumulation of beta-amyloid protein in the brain. However, the new research from a team at UC Berkeley reveals that superior amounts of deep, slow-wave sleep can act as a protective factor against decline in those with existing high amounts of Alzheimer’s disease —a potentially significant advance that experts say could help alleviate some of dementia’s most devastating outcomes.

“With a certain level of brain pathology, you’re not destined for cognitive symptoms or memory issues,” said Zsófia Zavecz, a postdoctoral researcher at UC Berkeley’s Center for Human Sleep Science. “People should be aware that, despite having a certain level of pathology, there are certain lifestyle factors that will help moderate and decrease the effects.

Read more | >

Researchers at the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute at the Cleveland Clinic in Ohio have authored a case report on the positive effects of psilocybin on color blindness.

Published in the journal Drug Science, Policy and Law, the researchers highlight some implications surrounding a single reported vision improvement self-study by a colleague and cite other previous reports, illustrating a need to understand better how these psychedelics could be used in therapeutic settings.

Past reports have indicated that people with deficiency (CVD), usually referred to as , experience better color vision after using lysergic acid diethylamide (LSD) or psilocybin (magic mushrooms). There is a lack of scientific evidence for these claims, as researching the effects of these drugs has been highly restricted.

Read more | >